Eli Lilly (LLY) Gets a Big Price Target Boost, Analysts See 20% Upside
Berenberg upgraded its rating on Eli Lilly and Company from Hold to Buy and increased its price target from $1,220 to $1,400. The firm cited the company's robust returns on investment and growth within the obesity treatment sector. Their 2026 return on research investment analysis supports this assessment, revealing the company's history of generating superior returns.
Berenberg anticipates a possible 25% stock price increase and expects Eli Lilly to surpass its fiscal 2026 projections. The company's Zepbound and Mounjaro treatments have established dominance in obesity and diabetes treatment markets. Furthermore, Berenberg anticipates that Foundayo, an oral GLP-1 drug with an expected diabetes approval, will spur significant demand.
Additionally, Eli Lilly's $60 billion in business development deals this year and potential for further investments are viewed favorably.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
